USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY

Bernadett Farkas  ¹     Mariann Borsos  ²     Tamás Resál  ²     Péter Bacsur  ²     Anita Balint  ²     Zoltán Szepes  ²     Renáta Bor  ²     Anna Fabian  ²     Edoardo Vincenzo Savarino  ^{3, 4}     Luisa Bertin  ^{3, 4}     Pal Miheller  ⁵     Fruzsina Vilmos  ⁵     Jimmy K. Limdi  ⁶     Karishma Sethi  ⁶     Fabiana Castiglione  ⁷     Fabiana Castiglione  ⁷     Milan Lukas  ⁸     Nitsan Maharshak  ^{9, 10}     Galia Berman  ^{9, 10}     Georgios Michalopoulos  ¹¹     Davide Giuseppe Ribaldone  ¹²     Anna Kagramanova  ^{13, 14}     Elena Chashkova  ^{15, 16}     Tamás Molnár  ¹⁶     Klaudia Farkas  ^16    
1 Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary
² AdWare Research, Balatonfüred, Hungary
³ University of Padua, Padua, Italy
⁴ Azienda Ospedale Università of Padua, Padua, Italy
⁵ Semmelweis University, Budapest, Hungary
⁶ The Northern Care Alliance Hospitals NHS Foundation Trust, Manchester, United Kingdom
⁷ University of Naples Federico II, Naples, Italy
⁸ ISCARE IVF Clinical Center Českomoravská, Prague, Prague, Czechia
⁹ Tel Aviv University, Tel Aviv, Israel
¹⁰ Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
¹¹ General Hospital of Athens "G. Gennimatas", Athens, Greece
¹² University of Turin, Turin, Italy
¹³ Moscow Clinical Scientific Center named after A. S. Loginov, Moscow, Russian Federation
¹⁴ Research Institute of Health Organization and Medical Management, Moscow, Russian Federation
¹⁵ Federal Scientific Center of Surgery and Traumatology, Irkutsk, Russian Federation
¹⁶ Irkutsk Regional Hospital, Irkutsk, Russian Federation

Topic
IBD

Session
PP 05 IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)